The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity of REM-422, a MYB mRNA degrader, in recurrent/metastatic adenoid cystic carcinoma: Final results from the phase 1/2 dose-escalation cohort.
 
Renata Ferrarotto
Consulting or Advisory Role - Answers in CME; Bicara Therapeutics; Coherus Biosciences; Eisai; Johnson & Johnson/Janssen; Labcorp Drug Development; Pyxis; Raptor Pharmaceuticals; Regeneron; Rgenta
Research Funding - Avacta Life Sciences (Inst); Bicara Therapeutics (Inst); Gilead Sciences (Inst); ISA Pharmaceuticals (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Remix Therapeutics (Inst); Rgenta (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties on UpToDate chapter on olfactory neuroblastoma, ~ 300 dollars per year
Travel, Accommodations, Expenses - Bicara Therapeutics
 
Paul Swiecicki
Employment - University of Michigan
Honoraria - Janssen Research & Development
Research Funding - Ascentage Pharma Group (Inst); Astellas Pharma (Inst); Coherus Biosciences (Inst); Janssen Oncology (Inst); Kineta (Inst); LigaChem Biosciences (Inst); Regeneron (Inst); Remix Therapeutics (Inst); Rgenta (Inst); Summit Therapeutics (Inst); Volastra Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a patent pending related to HPV ctDNA assay technology
 
Alan Ho
Honoraria - Horizon CME
Consulting or Advisory Role - AffyImmune Therapeutics; Cantor Fitzgerald; Day One Biopharmaceuticals; GlaxoSmithKline; Immunome; InhibRx; Johnson & Johnson/Janssen; National Cancer Institute; Pyxis; Remix Therapeutics; Rgenta Therapeutics; Takeda
Speakers' Bureau - Miami Cancer Research Center; Mt. Sinai; New York University (NYU); Northwell Health; Physicans' Education Resource
Research Funding - Astellas Pharma; AstraZeneca; Avacta Life Sciences; Ayala Pharmaceuticals; Bayer; Bayer; BioAtla; Bristol-Myers Squibb; Daiichi; Eisai; Genentech/Roche; Hookipa Biotech; Kura Oncology; Merck; Novartis; OncC4; Poseida; Remix Therapeutics; Rgenta; TILT Biotherapeutics; Verastem
Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN
Travel, Accommodations, Expenses - Hookipa Pharma; Lepu Biopharma; Remix Therapeutics
Other Relationship - Hookipa Biotech; Lepu Biopharma
(OPTIONAL) Uncompensated Relationships - Alliance for Clinical Trials in Oncology; HPV Cancer Alliance; International Thyroid Oncology Group
 
Alain Algazi
Stock and Other Ownership Interests - Onchilles Pharma; Sensei Biotherapeutics; Valitor
Consulting or Advisory Role - Onchilles Pharma; Sensei Biotherapeutics; Worldwide Clinical Trials
Research Funding - Acerta Pharma (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Genentech (Inst); Idera (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Oncosec (Inst); OncoSec (Inst); Sensei Biotherapeutics (Inst); Tessa Therapeutics (Inst); Vaccinex (Inst)
Travel, Accommodations, Expenses - OncoSec
 
Meredith McKean
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Daiichi Sankyo (Inst); IDEAYA Biosciences (Inst); IQvia (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Regeneron (Inst); Revolution Medicines (Inst)
Research Funding - Arcus Biosciences (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Erasca, Inc (Inst); GenVivo (Inst); Gilead Sciences (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); immatics (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Jazz Pharmaceuticals (Inst); Kezar Life Sciences (Inst); Krystal Biotech (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nested Therapeutics (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Pfizer (Inst); Pierre Fabre (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Repimune (Inst); Sapience Therapeutics (Inst); Synthorx (Inst); Teva (Inst); TScan Therapeutics (Inst)
 
Jennifer Webster
Employment - Remix Therapeutics
Leadership - Remix Therapeutics
Stock and Other Ownership Interests - Remix Therapeutics
Travel, Accommodations, Expenses - Remix Therapeutics
 
Mythili Koneru
Employment - Remix Therapeutics
Leadership - Remix Therapeutics
Stock and Other Ownership Interests - Remix Therapeutics
Travel, Accommodations, Expenses - Remix Therapeutics
 
Charles Kung
Employment - Remix Therapeutics
Leadership - Remix Therapeutics
Stock and Other Ownership Interests - Remix Therapeutics
Travel, Accommodations, Expenses - Remix Therapeutics
 
Glenn Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Massachusetts Medical Society
Consulting or Advisory Role - Adela; Astellas Pharma; AstraZeneca; Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Coherus Biosciences; Coherus Biosciences; CorriXr; Curie.Bio; Elevar Therapeutics; Grey Wolf Therapeutics; Guardian Bio; InhibRx; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Nextech Invest; OncoSwitch; Ottimo; Outrun; PDS Biotechnology; Pyxis; Regeneron; Remix Therapeutics; Replimune; Rgenta; Surface Oncology; TD Cowan; Tubulis GmbH
Research Funding - Actuate Therapeutics (Inst); Adenoid Cystic Carcinoma Research Foundation (Inst); ASCO (Inst); Astellas Pharma (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Cellestia Biotech (Inst); Coherus Biosciences (Inst); Exelixis (Inst); Gateway for Cancer Research; Genentech (Inst); ImmunityBio (Inst); KSQ Therapeutics (Inst); Kura Oncology (Inst); PHASE ONE Foundation (Inst); Regeneron (Inst); Remix Therapeutics (Inst); Rgenta (Inst); Secura Bio (Inst); Secura Bio (Inst)
Other Relationship - Tubulis GmbH